Skip to main content

4 Result(s)

within Omprakash Shriwas Remove this filter

and

  1. Article

    Open Access

    CRISPR-based kinome-screening revealed MINK1 as a druggable player to rewire 5FU-resistance in OSCC through AKT/MDM2/p53 axis

    Cisplatin, 5FU and docetaxel (TPF) are the most common chemotherapy regimen used for advanced OSCC. However, many cancer patients experience relapse, continued tumor growth, and spread due to drug resistance, ...

    Sibasish Mohanty, Pallavi Mohapatra, Omprakash Shriwas, Shamima Azma Ansari… in Oncogene (2022)

    Download PDF (4872 KB) View Article

  2. Article

    Correction: RRBP1 rewires cisplatin resistance in oral squamous cell carcinoma by regulating Hippo pathway

    Omprakash Shriwas, Rakesh Arya, Sibasish Mohanty… in British Journal of Cancer (2021)

    Download PDF (225 KB) View Article

  3. No Access

    Article

    RRBP1 rewires cisplatin resistance in oral squamous cell carcinoma by regulating Hippo pathway

    Chemoresistance is one of the major factors for treatment failure in OSCC. Identifying key resistance triggering molecules will be useful strategy for develo** novel treatment methods.

    Omprakash Shriwas, Rakesh Arya, Sibasish Mohanty… in British Journal of Cancer (2021)

  4. No Access

    Article

    DDX3 modulates cisplatin resistance in OSCC through ALKBH5-mediated m6A-demethylation of FOXM1 and NANOG

    Platinum based drugs alone or in combination with 5FU and docetaxel are common regimen chemotherapeutics for the treatment of advanced OSCC. Chemoresistance is one of the major factors of treatment failure in ...

    Omprakash Shriwas, Manashi Priyadarshini, Sabindra K. Samal, Rachna Rath… in Apoptosis (2020)